News | June 24, 2022
Merck KGaA doubles HPAPI production capacity in Wisconsin
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The drug will be manufactured at the group’s topical facility at Ahmedabad
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Subscribe To Our Newsletter & Stay Updated
